Improving the care of Lassa fever patients: re-evaluating the use of Ribavirin and characterising cardiovascular function
<p>Lassa fever is a viral haemorrhagic fever, endemic to several West African countries. Case fatality rates average 30% across the literature. Ribavirin, a broad-spectrum antiviral agent, has been used to treat Lassa fever for four decades. Ribavirin is a pro-drug, metabolised to its active m...
Main Author: | Salam, A |
---|---|
Other Authors: | Horby, P |
Format: | Thesis |
Language: | English |
Published: |
2024
|
Subjects: |
Similar Items
-
Two Cases of Lassa Fever Successfully Treated with Ribavirin and Adjunct Dexamethasone for Concomitant Infections
by: Sylvanus Okogbenin, et al.
Published: (2022-10-01) -
Animal Models of Lassa Fever
by: Rachel A. Sattler, et al.
Published: (2020-03-01) -
Addressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge
by: Qudus Olajide Lawal, et al.
Published: (2024-07-01) -
Bibliometric analysis of global Lassa fever research (1970–2017): a 47 – year study
by: Henshaw Uchechi Okoroiwu, et al.
Published: (2018-12-01) -
Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies
by: Hung-Yuan Cheng, et al.
Published: (2022-08-01)